Results

1–10 of 16 results for Dosing

Baseline Characteristics of Patients Who Did or Did Not Maintain 12-Week and 16-Week Aflibercept 8 mg Dosing Intervals in the Phase 2/3 PHOTON Trial
Eric W Schneider, MD
Annual Meeting Talks
2023
Impact of Initial Monthly Doses of Aflibercept on Visual Outcomes in Eyes With Diabetic Macular Edema in Routine Clinical Practice in the US
Ferhina S Ali, MD, MPH
Annual Meeting Talks
2023
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023
Baseline Characteristics of Patients Maintaining q12 and q16 Dosing With Aflibercept 8 mg vs Patients With Shortened Treatment Intervals Phase 3 PULSAR Post Hoc Analysis
David R. Chow, MD, FRCS(C)
Annual Meeting Talks
2023
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
It’s the Patient, Not the Agent: An Assessment of Anti-VEGF Extended Dosing Intervals in Patients With nAMD
David A. Eichenbaum, MD, FASRS
On Demand Cases, Courses, and Papers
2019
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Updates from the Field
2019
FIDO Study: 10-Year Outcomes of Eyes Receiving Continuous, Fixed-Interval Dosing of Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Ivan J. Suner, MD, MBA
Annual Meeting Talks
2019
BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing
Eric W Schneider, MD
Annual Meeting Talks
2019
Extended Q16W Dosing Potential for Faricimab in Neovascular Age-Related Macular Degeneration (nAMD): STAIRWAY Phase 2 Trial
Philip J. Ferrone, MD, FASRS
Annual Meeting Talks
2019